Molecular Search Candidate Assurance
A pre-pilot evidence gate for molecular-search candidate sets. It helps discovery teams separate cleaner, more review-ready search hits from duplicates and weakly supported candidates before downstream work consumes more budget.
Who this is for
Computational discovery teams
Teams generating more molecular-search candidates than specialists can review manually.
Candidate-triage teams
Teams deciding which search hits deserve deeper scientific review.
Discovery program leads
Decision-makers trying to reduce wasted downstream work on duplicate or weakly supported candidates.
The problem you already have
Search volume can exceed scientific review capacity
High-throughput molecular search can produce more candidates than specialists can inspect efficiently. Part 29's geometric drug-discovery disclosure provides a scientific basis for comparing molecule-to-pocket fit and candidate-level geometric evidence, but S32 deliberately sits after the upstream search step as a bounded evidence gate rather than claiming to replace the search engine itself.
A strong search hit can still be weak as a review candidate
A candidate can rank highly upstream while still carrying duplicate, identity-cleanliness or evidence-readiness concerns in the S32 pre-pilot record. The useful commercial decision is therefore not “is this molecule experimentally good?” but “is this candidate clean and supported enough to justify deeper scientific review?”
Computational candidate evidence is not experimental validation
Part 29 provides a drug-discovery computation lineage, while the current S32 truth-lock remains synthetic-only and pre-pilot. Candidate ordering, duplicate flags and review-readiness evidence therefore stay separate from synthesis success, binding validation, assay efficacy, safety or clinical claims.
Real-World Operational Scenario: The Top-Ranked Search Hit That Was Not Ready to Advance
Scenario: An upstream molecular search returns a large candidate set with several apparently strong hits.
A discovery team has limited specialist time and needs to choose which candidates deserve deeper review. One of the highest-ranked hits looks attractive, but its record is duplicated elsewhere in the set and its supporting evidence is weaker than a lower-ranked alternative.
WITHOUT this gate: The upstream rank can dominate the decision, causing duplicate or weakly supported candidates to consume downstream chemistry, modeling or assay budget too early.
WITH this gate: S32 separates candidate identity cleanliness, duplicate/evidence flags and review readiness from the upstream search score. The team receives a bounded ordering for the next review stage, with unsupported candidates held rather than presented as experimentally validated leads.
What BivectorAI Provides
Candidate Evidence Gate
Applies a consistent post-search review contract to the agreed synthetic candidate set so candidate promotion is based on evidence readiness rather than upstream rank alone.
Identity and Duplicate Review
Preserves the existing S32 duplicate and identity-cleanliness checks as explicit hold conditions before a candidate consumes deeper review effort.
Scientific Review Ordering
Produces a bounded next-stage ordering that can incorporate the supplied molecular-search context while remaining separate from claims of experimental affinity, synthesis success or assay performance.
Pre-Pilot Evidence Boundary
Returns a reviewable evidence package for program triage while keeping wet-lab validation, clinical interpretation and proprietary implementation details outside the public product claim.
Prove the Gate Before Broader Integration
Back-test the gate against a frozen synthetic candidate set with a known expert-review disposition.
Freeze the candidate schema, duplicate rules, evidence-readiness criteria and promotion/hold definitions before revealing which candidates experts previously advanced. A broader discovery pilot is justified only if the same gate reproducibly separates review-ready candidates from duplicates and weak records without turning computational screening into experimental validation.
What you provide
For the current pre-pilot stage, an agreed synthetic candidate set and the minimum search-result context needed for evidence review.
What BivectorAI actually hands you
Candidate review ordering
A bounded ordering of candidates for the next review stage.
Duplicate and evidence flags
Cases requiring additional review are separated from cleaner candidate records.
Review-readiness evidence
A compact explanation of why a candidate should advance, hold or receive more evidence.
Pre-pilot report
A record for deciding whether a larger discovery pilot is justified.
What we will never ask you for
Molecular discovery programs often protect compound libraries, wet-lab protocols and search-system internals. The current pre-pilot review uses an agreed synthetic candidate set and only the search-result context needed for evidence review, so those protected assets stay outside the engagement.
- your complete proprietary compound library;
- wet-lab execution protocols;
- source code for your molecular-search system;
- unrelated confidential research data.
How it actually runs
Strategic commercial terms
Strategic technology — direct commercial agreement only. No automated checkout applies to this line.
We do not open with an annual license. The first engagement is a fixed-scope evaluation. If it does not add useful decision evidence over your current review process, there is no reason to move into a broader commercial commitment; you keep the evaluation record and stop there.
Pre-pilot candidate evaluation
Fixed scope
Quoted per engagement, with no ongoing commitment required for the initial evaluation.
One agreed synthetic candidate set, with no downstream experimental commitment.
Private integration / NRE
On request
Environment setup, evidence mapping, acceptance definition and controlled engagement scope.
Annual technology license
On request
Ongoing access within the agreed field, program and deployment boundary.
Program / campaign
On request
A bounded program where the assessment produces substantial exportable decision evidence.
Tier: S-DISCOVERY. Strategic discovery / extraction-value program.
Exclusive field-of-use rights, sublicensing, source-level technical data, IP assignment, unusually broad bulk usage and dedicated infrastructure are negotiated separately.
Scope the S32 engagement
Request S32 Strategic Discussion →Email fallback: contact@bivectorai.com
Current boundary: Current evidence status: pre-pilot and synthetic-only. No experimental or field validation is claimed for S32 at this stage.
Protected implementation details remain outside the public commercial description.